Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
NCT04419467
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
114
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetic Kidney Disease (DKD)
Interventions
BIOLOGICAL:
CSL346
DRUG:
Placebo
Sponsor
CSL Behring